Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: In vivo efficacy of siRNA-liposomes

• Published in: Biochimica et biophysica acta Vol. 1780; no. 1; pp. 34 - 40
• Main Authors: Jing, Yawu, Shishkov, Andrei, Ponnappa, Biddanda C.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2008
• Subjects: Animals; Enzyme-Linked Immunosorbent Assay; Injections, Intravenous; Kupffer cells; Kupffer Cells - cytology; Kupffer Cells - drug effects; Kupffer Cells - metabolism; Lipopolysaccharide; Lipopolysaccharides - pharmacology; Liposomes; Liposomes - chemistry; Male; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Messenger - metabolism; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - chemistry; RNA, Small Interfering - genetics; siRNA; Time Factors; TNF alpha; Tumor Necrosis Factor-alpha - blood; Tumor Necrosis Factor-alpha - genetics; Tumor Necrosis Factor-alpha - metabolism; Lipopolysaccharide; siRNA; TNF alpha; Liposomes; Kupffer cells
• ISSN: 0304-4165; 0006-3002; 1872-8006
• DOI: 10.1016/j.bbagen.2007.09.015

Tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine, plays a key role in the pathogenesis of many inflammatory diseases, including alcoholic liver disease.  In the liver, Kupffer cells are the primary source of the cytokine. Obliteration of Kupffer cells or neutralization of TNF-α by anti-TNF-α antibody or by an antisense oligonucleotide prevents ethanol-mediated liver damage. In this study, we report the identification of yet another highly efficacious gene-silencing molecule, the short interfering RNA (siRNA), SSL3, against TNF-α. The efficacies of various siRNA duplexes were tested against TNF-α mRNA in primary cultures of rat Kupffer cells. SSL3 (25 nM) inhibited lipopolysaccharide (LPS)-induced secretion of TNF-α by 55% ( p < 0.005) with a proportionate reduction in TNF-α mRNA; the inhibitory effect lasted for at least 96 h. Four nucleotide mismatches to SSL3 completely abolished the inhibitory effects of SSL3, suggesting the sequence specificity of the siRNA. Further, the in vivo efficacy of SSL3 was assessed following the i.v. administration of two doses (140 μg/kg body weight/day for 2 days) of liposome-encapsulated SSL3. The LPS-induced TNF-α secretion was inhibited by > 60% ( p < 0.05) by SSL3 pre-treatment. These data demonstrate the identification of an siRNA against TNF-α, which, as a liposomal formulation, has therapeutic potential in the treatment of inflammatory diseases mediated by TNF-α.